Closing the Hepatitis B Diagnosis Gap in Africa Through Innovation
Africa currently faces a significant clinical research disparity regarding the hepatitis B virus (HBV), despite the continent accounting for approximately 65% of global new infections. While 68 million individuals in the region live with chronic HBV, only 1% of global clinical trials for the condition are conducted within African nations, according to a personal view published in The Lancet Microbe in January 2026.
Key Clinical Takeaways:
- Africa bears a substantial burden of chronic hepatitis B, yet remains critically underrepresented in therapeutic clinical trials.
- Barriers to research include systemic gaps in healthcare infrastructure, insufficient political will, and a lack of dedicated funding for region-specific clinical studies.
- Addressing the disparity requires a shift toward African-led research that accounts for unique viral genotypes and prevalent co-infections like HIV.
The Disparity in Hepatitis B Clinical Trials
As of May 2023, global registries indicated that only 18 out of 1,804 HBV clinical trials were hosted in the WHO African region. This lack of localized data limits the generalizability of therapeutic findings, particularly as the global pipeline for HBV treatment shifts toward functional cure candidates. The research environment is further complicated by the high prevalence of diverse HBV genotypes and frequent co-infections with HIV and the hepatitis D virus, which may influence both the pathogenesis of the disease and the efficacy of novel pharmaceutical agents.
According to the Journal of Medical Internet Research, bridging the diagnosis and treatment gap requires innovation that extends beyond digital interventions. While digital health tools can improve data collection, they cannot replace the foundational need for robust clinical infrastructure and diagnostic capacity.
Barriers to Implementation and Research Capacity
The underutilization of existing research networks in Africa remains a primary concern for the scientific community. While the continent successfully mobilized infrastructure for HIV, malaria, and COVID-19 research, these networks are frequently bypassed in the context of HBV. Authors of the The Lancet Microbe analysis, including Mitchell Leus and colleagues, highlight that inadequate funding, regulatory systems, and low community-level awareness remain the most persistent hurdles to scaling clinical trials.
The current standard of care—lifelong suppressive antiviral therapy—is often inaccessible to the vast majority of the population. In 2022, only 0.2% of those living with chronic HBV in Africa received this treatment.
Strategic Path Toward Regional Equity
To rectify these imbalances, experts advocate for the establishment of industry funding consortiums and the strengthening of national regulatory frameworks. By leveraging existing clinical research platforms, African investigators can ensure that therapeutic trials are tailored to the specific environmental and host-related factors of the region. This transition is essential for ensuring that future treatments are not only safe but effective for the specific demographic profiles found in the region.
Future Trajectory of HBV Research
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.